EDAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EDAP is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong operational momentum and positive sentiment from hedge funds, but the technicals show it is overbought after a sharp move, and the latest quarter still shows losses. Because the user is impatient and wants a direct answer, my view is to hold off on a new purchase now and wait for a better entry rather than buy at this price.
EDAP is in a bullish trend technically: MACD histogram is positive and expanding, and the moving averages are stacked bullishly with SMA_5 > SMA_20 > SMA_200. However, RSI_6 is 86.663, which is heavily overbought and suggests the recent rally is stretched. Price at 3.90 is below the prior close of 4.16, with key support at 3.612 and resistance at 4.032 and 4.292. The short-term setup is strong, but the current level is not an attractive low-risk entry for long-term buying after the recent surge.
["Q1 2026 revenue hit a record $17.81M, up 24.96% YoY.", "HIFU revenue was $11.6M, up 78% YoY, with record U.S. procedure volumes.", "Hedge funds were strong buyers, with buying up 13,044.55% over the last quarter.", "Analyst H.C. Wainwright maintained a Buy rating despite cutting the price target to $10 from $14.", "Positive options sentiment with low put-call ratios indicates bullish trader positioning."]
["Q1 2026 GAAP EPS was -$0.24, missing expectations and showing the company is still unprofitable.", "Net income remained negative at -$9.083M.", "The stock has become technically overbought after a sharp rally, increasing the chance of near-term cooling.", "Price target was reduced from $14 to $10, showing reduced analyst optimism even while keeping a Buy rating.", "Similar candlestick pattern data suggests mild near-term downside or flat performance."]
In Q1 2026, EDAP delivered strong top-line growth with revenue of $17.81M, up 24.96% year over year. Gross margin held at 45.73%, which is solid. The main weakness is profitability: net income was -$9.083M and EPS was -$0.24, although both improved year over year. Overall, the latest quarter season was Q1 2026 and it showed healthy growth trends but continued losses.
Analyst sentiment is still constructive but less aggressive than before. H.C. Wainwright kept a Buy rating but lowered the price target from $14 to $10, indicating continued upside belief with a more conservative valuation view. Wall Street pros appear positive on the company’s strategic progress and Q1 execution, but the reduced target suggests some caution about near-term upside.
